The effect of transurethral alprostadil on the quality of life of men with erectile dysfunction, and their partners. MUSE Study Group.

Br J Urol 1998 Dec;82(6):847-54

Service d'Urologie, Hôpital Henri Mondor, Creteil, France.

Objective: To evaluate the impact of treatment for erectile dysfunction on the quality of life of men and their partners.

Patients And Methods: The study included 249 men with organic erectile dysfunction of more than 3 months' duration who self-administered transurethral alprostadil in an open-label, dose-escalating manner in an outpatient medical setting. Patients with a sufficient response (159) were randomly assigned in a double-blind protocol to either active medication or placebo for 3 months at home. Patients and partners each completed quality-of-life questionnaires before and after treatment.

Results: In the clinic 159 of the 249 men (64%) had an erection sufficient for intercourse when using transurethral alprostadil. At home, 46 of 67 men (69%) reported intercourse at least once on transurethral alprostadil, compared with eight of 73 (11%) on placebo (P < 0.001). Patients on alprostadil showed a 34% improvement in their 'relationship with partner', a 5% improvement in 'personal wellness', and a 71% improvement in 'quality of erection' domains, compared with a decline of 11%, 8% and 1%, respectively, in patients on placebo (P < 0.005 for each comparison). Partners of patients on alprostadil showed a 35% improvement in the 'relationship with partner' domain, compared with a 12% improvement in the placebo group (P = 0.028). There was a trend toward improvement in other partner domains. Urogenital pain was reported by 14% of patients during home treatment.

Conclusion: The resumption of sexual intercourse with the use of transurethral alprostadil was accompanied by an improvement in several important quality-of-life domains in patients and their partners.
December 1998
9 Reads

Publication Analysis

Top Keywords

transurethral alprostadil
intercourse transurethral
erectile dysfunction
life men
improvement 'relationship
249 men
quality life
patients alprostadil
'relationship partner'
patients partners
0001 patients
wellness' 71%
placebo 0001
71% improvement
11% placebo

Similar Publications

Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group.

Br J Urol 1998 Jun;81(6):889-94

Department of Surgery, Hammersmith Hospital, London, UK.

Objective: To examine the safety and efficacy of transurethral pharmacotherapy for erectile dysfunction, involving the use of a novel therapeutic system to administer alprostadil (prostaglandin E1) to the urethral mucosa in a double-blind, randomized, parallel, placebo-controlled study conducted in five countries in Europe.

Patients And Methods: In an outpatient setting, patients with primarily organic erectile dysfunction of at least 3 months' duration were treated with transurethral alprostadil, in an open-label, dose-escalating study. Testing stopped when the dose provided an erection sufficient for intercourse, as assessed by the patient and the investigator. Read More

View Article
June 1998

Transurethral alprostadil as therapy for patients who withdrew from or failed prior intracavernous injection therapy.

Urology 1998 May;51(5):687-92

Department of Urology, Northwestern University Medical School, Chicago, Illinois, USA.

Objectives: Patients experiencing erectile dysfunction who fail intracavernous injection (ICI) therapy are commonly believed to have exhausted pharmacologic options. We evaluated the efficacy and safety of transurethral alprostadil (MUSE) in patients experiencing erectile dysfunction who underwent prior ICI therapy (alprostadil, papaverine, phentolamine, or a combination of these).

Methods: Of the 1511 patients enrolled in a multicenter trial of transurethral alprostadil, 452 (30%) reported prior ICI therapy and its effects. Read More

View Article
May 1998

Multicenter study of the treatment of erectile dysfunction with transurethral alprostadil (MUSE) in Korea.

Int J Impot Res 2000 Apr;12(2):97-101

Department of Urology, Chung-Ang University Yongsan Hospital, Seoul, Korea.

A Korean multicenter study was conducted to assess the effectiveness of transurethral alprostadil with MUSE in 334 subjects with chronic erectile dysfunction (ED) who were enrolled in 21 clinical centers. Patients with psychogenic impotence comprised about 30% of subjects. Intraurethral alprostadil was titrated in a stepwise fashion in the clinics from 250 to 500 or 1000 mcg based on erectile response and tolerability. Read More

View Article
April 2000

Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group.

N Engl J Med 1997 Jan;336(1):1-7

Department of Urology, University of Southern California, Los Angeles, USA.

Background: Erectile dysfunction in men is common. We evaluated a system by which alprostadil (prostaglandin E1) is delivered transurethrally to treat this disorder.

Methods: Alprostadil was delivered transurethrally in a double-blind, placebo-controlled study of 1511 men, 27 to 88 years of age, who had chronic erectile dysfunction from various organic causes. Read More

View Article
January 1997